Celsis Join with Bioventures to Develop Next Generation Rapid Detection Products
Celsis International have signed an exclusive licensing agreement with BioVentures Inc. to develop next generation products for rapid microbial and virus detection.
The objective of such products is to enable the real-time and accurate detection of contamination for customers in the pharmaceutical, biotechnology, personal care and beverage industries, so saving costs and time and preventing the need for product recalls.
Screening for contamination has become an essential part of the manufacturing process as customers increasingly recognise the vital importance of ensuring product quality and consumer safety. Celsis currently offers manufacturers rapid testing solutions, which provide results in 18 - 24 hours.
The products developed through this agreement will benefit customers by significantly reducing the time to results to a few hours or less, while providing more information than permitted by current testing methodologies.
This new licensing agreement covers BioVentures’ patented and patent pending high density microarray technology which offers revolutionary improvements to the consistency, reproducibility and cost effectiveness of microarrays. Additionally, the BioVenture microarray offers improved design flexibility allowing for increased sensitivity and ease of interpretation. The joint development plan will also encompass nucleic acid testing and other rapid detection technologies.
|
